tetano
Editor, Senior Moderator
Nat Commun
. 2024 Mar 28;15(1):2734.
doi: 10.1038/s41467-024-46982-6. The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
Daming Zhou[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Piyada Supasa[SUP] #[/SUP][SUP] 1 4 [/SUP], Chang Liu[SUP] #[/SUP][SUP] 1 4 [/SUP], Aiste Dijokaite-Guraliuc[SUP] #[/SUP][SUP] 4 [/SUP], Helen M E Duyvesteyn[SUP] #[/SUP][SUP] 2 [/SUP], Muneeswaran Selvaraj[SUP] 4 [/SUP], Alexander J Mentzer[SUP] 4 5 [/SUP], Raksha Das[SUP] 4 [/SUP], Wanwisa Dejnirattisai[SUP] 6 [/SUP], Nigel Temperton[SUP] 7 [/SUP], Paul Klenerman[SUP] 5 8 9 [/SUP], Susanna J Dunachie[SUP] 5 10 11 [/SUP], Elizabeth E Fry[SUP] 12 [/SUP], Juthathip Mongkolsapaya[SUP] 13 14 15 [/SUP], Jingshan Ren[SUP] 16 [/SUP], David I Stuart[SUP] 17 18 19 [/SUP], Gavin R Screaton[SUP] 20 21 [/SUP]
Affiliations
Under pressure from neutralising antibodies induced by vaccination or infection the SARS-CoV-2 spike gene has become a hotspot for evolutionary change, leading to the failure of all mAbs developed for clinical use. Most potent antibodies bind to the receptor binding domain which has become heavily mutated. Here we study responses to a conserved epitope in sub-domain-1 (SD1) of spike which have become more prominent because of mutational escape from antibodies directed to the receptor binding domain. Some SD1 reactive mAbs show potent and broad neutralization of SARS-CoV-2 variants. We structurally map the dominant SD1 epitope and provide a mechanism of action by blocking interaction with ACE2. Mutations in SD1 have not been sustained to date, but one, E554K, leads to escape from mAbs. This mutation has now emerged in several sublineages including BA.2.86, reflecting selection pressure on the virus exerted by the increasing prominence of the anti-SD1 response.
. 2024 Mar 28;15(1):2734.
doi: 10.1038/s41467-024-46982-6. The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
Daming Zhou[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Piyada Supasa[SUP] #[/SUP][SUP] 1 4 [/SUP], Chang Liu[SUP] #[/SUP][SUP] 1 4 [/SUP], Aiste Dijokaite-Guraliuc[SUP] #[/SUP][SUP] 4 [/SUP], Helen M E Duyvesteyn[SUP] #[/SUP][SUP] 2 [/SUP], Muneeswaran Selvaraj[SUP] 4 [/SUP], Alexander J Mentzer[SUP] 4 5 [/SUP], Raksha Das[SUP] 4 [/SUP], Wanwisa Dejnirattisai[SUP] 6 [/SUP], Nigel Temperton[SUP] 7 [/SUP], Paul Klenerman[SUP] 5 8 9 [/SUP], Susanna J Dunachie[SUP] 5 10 11 [/SUP], Elizabeth E Fry[SUP] 12 [/SUP], Juthathip Mongkolsapaya[SUP] 13 14 15 [/SUP], Jingshan Ren[SUP] 16 [/SUP], David I Stuart[SUP] 17 18 19 [/SUP], Gavin R Screaton[SUP] 20 21 [/SUP]
Affiliations
- PMID: 38548763
- PMCID: PMC10978878
- DOI: 10.1038/s41467-024-46982-6
Under pressure from neutralising antibodies induced by vaccination or infection the SARS-CoV-2 spike gene has become a hotspot for evolutionary change, leading to the failure of all mAbs developed for clinical use. Most potent antibodies bind to the receptor binding domain which has become heavily mutated. Here we study responses to a conserved epitope in sub-domain-1 (SD1) of spike which have become more prominent because of mutational escape from antibodies directed to the receptor binding domain. Some SD1 reactive mAbs show potent and broad neutralization of SARS-CoV-2 variants. We structurally map the dominant SD1 epitope and provide a mechanism of action by blocking interaction with ACE2. Mutations in SD1 have not been sustained to date, but one, E554K, leads to escape from mAbs. This mutation has now emerged in several sublineages including BA.2.86, reflecting selection pressure on the virus exerted by the increasing prominence of the anti-SD1 response.